<DOC>
	<DOCNO>NCT00602290</DOCNO>
	<brief_summary>This study evaluate safety effectiveness methylphenidate improve cognition function old adult depression .</brief_summary>
	<brief_title>Effectiveness Methylphenidate Improving Cognition Function Older Adults With Depression</brief_title>
	<detailed_description>Less 50 % old adult depression achieve remission functional recovery response first-line antidepressant treatment . Most left significant residual symptom , put risk illness relapse , frailty , suicide . Improved understanding neurobiology depression old adult mechanisms treatment response may lead good clinical management depression . Methylphenidate ( MPH ) long use elderly medically ill provide rapid improvement depression , apathy , fatigue . However , potential beneficial effect cognitive functional outcome older adult depression study . Combining MPH serotonergic antidepressant citalopram may result good clinical outcome would use citalopram alone . This study compare safety effectiveness MPH combine citalopram , MPH combine placebo , citalopram combine placebo improve thinking , memory , speed recovery old adult depression . The study also evaluate select dopamine- serotonin-related gene relationship mood , cognitive symptom , treatment response MPH citalopram . Participation double-blind study last 16 week . All potential participant initially undergo comprehensive medical , neuropsychiatric , cognitive assessment genetic testing . These initial assessment include questionnaire depressive symptom , medical history , electrocardiogram ( ECG ) , blood draw genetic testing . Eligible participant randomly assign one three group : MPH citalopram , MPH placebo , citalopram placebo . All participant receive 16 week treatment assign medication . Study visit occur weekly first 6 week treatment bi-weekly remainder study . During study visit , participant undergo vital sign weight measurement , answer questionnaire , report medication side effect . Blood drawn Visits 4 10 , ECG repeat Visit 10 cardiac symptom occur . Most initial assessment repeat Visit 13 , last study visit . Participants also contact weekly phone throughout study answer question feel possible side effect .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Meets Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) criteria major depressive disorder ( recurrent nonrecurrent course identify ) Score 16 high 24item Hamilton Depression Rating Scale ( HDRS ) study entry Score 26 high MiniMental State Exam ( MMSE ) History psychiatric illness substance abuse disorder unipolar depression , diagnose prior onset first depressive episode Presence psychotic symptom Severe acute medical illness ( e.g. , major surgery , metastatic cancer , stroke , heart attack ) 6 month prior study entry Acute suicidal violent behavior history suicide attempt within year prior study entry Presence delirium , neurodegenerative dementia , Parkinson 's disease , central nervous system ( CNS ) diseases Toxic metabolic abnormality laboratory examination Medications take medical illness present could account depression Active heart failure categorize Class III great accord New York Heart Association criterion Heart attack crescendo angina within 3 month prior study entry Symptomatic cardiac arrhythmia symptomatic , hemodynamically significant mitral aortic valvular disease Resting heart rate le 50 beat per minute correct QT ( QTc ) interval great 0.45 second Second third degree atrioventricular block Systolic blood pressure great 180 mmHg less 90 mmHg diastolic blood pressure great 105 mmHg less 50 mmHg study entry Treated depot neuroleptic therapy within 6 month prior study entry Treated neuroleptic , antidepressant , anxiolytic medication ( lorazepam ) , overthecounter CNSactive medication use treatment depression ( e.g , St. John 's Wort , kavakava , melatonin ) within 2 week ( 4 week fluoxetine monoamineoxidase inhibitor ( MAOIs ) ) prior first administration study medication Known allergy citalopram MPH history ineffective treatment citalopram MPH current depressive episode Requires concomitant therapy prescription overthecounter medication potentially dangerous interaction either citalopram MPH Requires electroconvulsive therapy ( ECT ) receive ECT within 3 month prior study entry Initiated psychotherapy within 3 month prior study entry initiate terminate psychotherapy study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Geriatric Major Unipolar Depression</keyword>
	<keyword>Executive Cognitive Dysfunction</keyword>
	<keyword>Elderly</keyword>
	<keyword>Geriatric</keyword>
	<keyword>Executive Cognitive Impairment</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Disability</keyword>
	<keyword>Comorbidity</keyword>
	<keyword>Medical Burden</keyword>
	<keyword>Safety</keyword>
	<keyword>Candidate Genes</keyword>
</DOC>